Plasma proteins |
Albumin, fibrinogen, globulin, and transferrin |
Improve hemocompatibility (Steinberg et al., 1989) |
Enhance plasma stability (Yeo et al., 2018) |
Reduce platelet adhesion (Neumann et al., 1979) |
Extracellular matrix proteins |
Collagen, elastin, fibronectin, vitronectin, and laminin |
Improved cell adhesion (Chen, Kawazoe and Tateishi, 2008) |
Increased wettability (Balaji et al., 2015) |
Antibodies |
Anti-CD3 and anti-CD28 |
T-cell activation (Neal et al., 2017) |
Anti-EGFR, anti-HER2, and anti-EpCAM |
Target tumor cells (Gibson et al., 2018; Oh et al., 2018; Ai et al., 2021) |
Antigen |
Ovalbumin |
Model antigen (Wang and Mooney, 2018) |
Peptides |
RGD motif containing peptides |
Cell adhesion (Pagel et al., 2016; Buxadera-Palomero et al., 2017) |
Tumor accumulation (Rios De La Rosa et al., 2020) |
NGR motif containing peptides |
Tumor tropism (Graziadio et al., 2016) |
Repeated sequence of PSA |
Stealth effect (Schlapschy et al., 2013) |
E14LKK/H14LKK |
Antimicrobial activities (Balaji et al., 2015) |
SIINFEKL |
Model epitope (Karandikar et al., 2019; Kramer et al., 2019) |